Associated Papers
Eosinophilic Cells in Endometrial Carcinoma as a Predictor of BRAF Mutation: Report of 2 Cases.
Lavis P et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 2026
Malignant struma ovarii: Advances in molecular pathogenesis, classification, diagnosis and treatment.
Lin W et al.
Histopathology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The molecular profile of ovarian struma ovarii.
Calejero I et al.
Human Pathology, 2026
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.
Sini C et al.
European Journal of Cancer (oxford, England : 1990), 2026
Oncogenic Alterations in PI3K Signaling Emulated Optogenetically Recapitulate Some Phenotypic Changes in Mammary Epithelia.
Gagnon KA et al.
Acs Synthetic Biology, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Molecular Mosaics: Unveiling Heterogeneity in Synchronous Colorectal Cancers.
Lee HG et al.
Cancer Research and Treatment, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls.
Hashmi AA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
Exploring Molecular Characteristics and Therapeutic Strategies for Primary Sinonasal Mucosal Melanoma With Distant Metastasis.
Ren D et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2025
Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.
Lv C et al.
Nature Aging, 2025
Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial.
Pardini E et al.
Thoracic Cancer, 2025
DNA polymerase epsilon-mutant colorectal cancers: Insights into non-exonuclease domain mutation variants, microsatellite instability status, and co-mutation profiles.
Taskiran I et al.
World Journal of Gastroenterology, 2025
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Smolenschi C et al.
Npj Precision Oncology, 2025
Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration.
Ubaid S et al.
Cancer Genetics, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
van der Wel JWT et al.
Lung Cancer (amsterdam, Netherlands), 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.
Lu K et al.
Npj Precision Oncology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Malignant struma ovarii: clinicopathological and molecular features in a series of nine cases.
Yang X et al.
Virchows Archiv : an International Journal of Pathology, 2025
Feasibility of a ctDNA multigenic panel for non-small-cell lung cancer early detection and disease surveillance.
Casagrande GMS et al.
Molecular Oncology, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
Manabe T et al.
Research Square, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Molecular Landscape of Pediatric Low-Grade Gliomas: Insights From RNA-NGS and Bioinformatic Analysis.
Brož P et al.
Genes, Chromosomes & Cancer, 2025
Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature.
Rausch C et al.
Bjc Reports, 2025
BRAF V600E liquid biopsy-based detection in precision oncology.
Mendeluk GR et al.
Advances in Laboratory Medicine, 2025
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations.
Zanwar S et al.
Blood Advances, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
Klocker EV et al.
Npj Breast Cancer, 2025
Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.
Kropf-Sanchen C et al.
Esmo Open, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders.
Esai Selvan M et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition.
Heidrich I et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.
Lin YB et al.
Head & Neck, 2025
Clinical Sequence Revealed the Prevalence and Biological Significance of Somatic Pathogenic Variants in Thoracic Cancer: Implications for Germline Status.
Fukushima T et al.
Clinical Lung Cancer, 2025
Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.
Nguyen HB et al.
Practical Laboratory Medicine, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.
Ciardiello D et al.
Esmo Open, 2025
Correction to "Efficacy of Trametinib in a Metastatic Urothelial Carcinoma Patient With a BRAF Mutation: A Case Report".
Unknown Author
Iju Case Reports, 2025
Whole-Exome Sequencing Analysis of Inflammatory Bowel Disease-Associated Serrated Dysplasia.
Balajthy Z et al.
International Journal of Molecular Sciences, 2025
The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the Oncomine Dx Target Panel at the PATHOS Molecular Pathology Laboratory.
Gaal OI et al.
Cancers, 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025